VIB spin-off MRM Health reports positive preclinical results in non-alcoholic fatty liver disease

Belgian scientists from VIB and Ghent University (UGent), together with Danish collaborators, have found that early-infancy infection with respiratory syncytial virus (RSV) increases the risk of developing childhood asthma

26 November 2025, Leuven, Belgium - Lecanemab, sold under the name Leqembi, is a monoclonal antibody therapy for Alzheimer’s disease that clears toxic amyloid plaques and delays cognitive decline. Researchers from VIB and KU Leuven have now demonstrated the mechanism behind it for the first time. They showed that the ‘Fc fragment’ of this monoclonal antibody is essential for engaging microglia - the immune cells of the brain -, thus initiating the cellular machinery needed for plaque removal. This is the first direct mechanistic explanation for how this class of therapies works. It clarifies uncertainties in the field and offers a blueprint for developing safer, more effective Alzheimer’s treatments. The findings are published in Nature Neuroscience.

World Amyloidosis Day – 26 October | First benefit concert supports new Fund